Detalhe da pesquisa
1.
Conditioning-based outcomes after allogeneic transplantation for myeloma following a prior autologous transplant (1991-2012) on behalf of EBMT CMWP.
Eur J Haematol
; 104(3): 181-189, 2020 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-31737951
2.
CD34+ Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >50 Years with Acute Myelogenous Leukemia and Myelodysplastic Syndrome .
Biol Blood Marrow Transplant
; 24(5): 964-972, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29305194
3.
Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma.
Biol Blood Marrow Transplant
; 22(10): 1808-1815, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27470290
4.
The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate.
Haematologica
; 98(4): 526-32, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23065527
5.
To freeze or not to freeze peripheral blood stem cells prior to allogeneic transplantation from matched related donors.
Eur J Haematol
; 91(5): 448-55, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23710624
6.
SF3B1, RUNX1 and TP53 Mutations Significantly Impact the Outcome of Patients With Lower-Risk Myelodysplastic Syndrome.
Clin Lymphoma Myeloma Leuk
; 22(12): e1059-e1066, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36117041
7.
Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study.
Bone Marrow Transplant
; 55(3): 641-648, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31700138
8.
Vitamin D Modifies the Incidence of Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation Depending on the Vitamin D Receptor (VDR) Polymorphisms.
Clin Cancer Res
; 25(15): 4616-4623, 2019 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31043390
9.
Evaluation of Parameters Related to the Probability of Leukemic Progression in Patients With Lower-Risk Myelodysplastic Syndrome.
Clin Lymphoma Myeloma Leuk
; 18(7): 469-474.e1, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29807802
10.
The incorporation of comorbidities in the prognostication of patients with lower-risk myelodysplastic syndrome.
Leuk Lymphoma
; 58(8): 1893-1902, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27951729
11.
Immunomodulatory Effect of Vitamin D after Allogeneic Stem Cell Transplantation: Results of a Prospective Multicenter Clinical Trial.
Clin Cancer Res
; 22(23): 5673-5681, 2016 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27358490
12.
Overexpression of GYS1, MIF, and MYC is associated with adverse outcome and poor response to azacitidine in myelodysplastic syndromes and acute myeloid leukemia.
Clin Lymphoma Myeloma Leuk
; 15(4): 236-44, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25487600
13.
Multivariable time-dependent analysis of the impact of azacitidine in patients with lower-risk myelodysplastic syndrome and unfavorable specific lower-risk score.
Leuk Res
; 39(1): 52-7, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25487012
14.
Patterns of infection in patients with myelodysplastic syndromes and acute myeloid leukemia receiving azacitidine as salvage therapy. Implications for primary antifungal prophylaxis.
Clin Lymphoma Myeloma Leuk
; 14(1): 80-6, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24220615
15.
Clinical prognostic factors for survival and risk of progression to acute myeloid leukemia in patients with myelodysplastic syndromes with < 10% marrow blasts and non-unfavorable cytogenetic categories.
Clin Lymphoma Myeloma Leuk
; 13(2): 144-52, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23137720